Research | 全球健康药物研发中心

Our Research

At GHDDI, we focus on translational research – from the bench to the bedside. Our scientists conduct great science and develop new technology to accelerate drug discovery for diseases that impact global population, such as COVID-19, tuberculosis, malaria etc. With diverse pipelines constructed, GHDDI have already achieved great number of breakthroughs.

RESEARCH PLATFORMS

GHDDI has successfully established an industry-leading standardized matrix system that acts as a cornerstone for the development of new small molecule drugs, with a sharp focus on multiple disease areas in the realm of biology. This state-of-the-art system is powered by medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), animal laboratory, protein science and structural biology, high-throughput screening, and data science. These cutting-edge platforms play a pivotal role in drug discovery, offering unmatched precision and efficiency.

AI KongMing Platform

AI KongMing is an integrated AI R&D platform for real-world drug discovery, combining cheminformatics, bioinformatics, pharmaceutical and medical data with physics-based modeling, deep learning, foundation models, and expert knowledge. It supports target assessment, molecular generation, virtual screening, activity and drug-likeness assessment, multi-parameter optimization, and Agent KongMing, an AI research agent that can understand scientific questions, conduct research, decompose tasks, plan workflows, and use specialized tools. Agent KongMing also connects disciplines, departments, and projects by integrating project progress, experimental data, expert input, and historical decisions to improve cross-team collaboration, and R&D decision-making. The platform is supported by more than 100 high-performance computing clusters for large-scale AI-driven drug discovery.

https://datascience.ghddi.org/

HTS

Equipped with the cutting-edge HighRes fully automated high-throughput screening system instrumentation, HTS supports multiple types of screening methods based on biological targets and cellular phenotypes. With a screening data capacity of millions of compounds (samples)/year, the platform can save time and cost. The platform has established multiple types of compound libraries, including known activity libraries, structural diversity libraries, natural product libraries, and true pair-specific disease/target libraries, with a total of over 450,000 compounds. In addition, the platform has the ReFRAME compound library, with over 12,000 clinically safe compounds.

http://hts.ghddi.org/